Mariaelena Serio

Scorrano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Journal: Advances in therapy

Published: February 11, 2026

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Journal: Journal of clinical medicine

Published: August 27, 2025

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Journal: Intestinal research

Published: April 29, 2025

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Journal: Journal of clinical medicine

Published: September 23, 2024

Multi-institutional study using sbrt to treat mediastinal and hilar lymphadenopathy.

Multi-institutional study using sbrt to treat mediastinal and hilar lymphadenopathy.

Journal: Clinical & experimental metastasis

Published: August 06, 2024

Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.

Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.

Journal: Expert opinion on biological therapy

Published: January 22, 2024

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.

Journal: Expert opinion on pharmacotherapy

Published: June 26, 2023

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.

Journal: Expert opinion on biological therapy

Published: February 27, 2023

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.

Journal: Journal of gastrointestinal and liver diseases : JGLD

Published: September 08, 2022

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.

Journal: Inflammatory bowel diseases

Published: January 24, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026